The MD Anderson Symptom Inventory for ovarian cancer (MDASI-OC) is a disease-specific MDASI module. Along with the core MDASI’s 13 symptom items and 6 interference items, the MDASI-OC also assesses 8 symptoms specific to ovarian cancer:
- abdominal pain
- feeling bloated
- problems with paying attention or concentrating
- urinary urgency
- pain or burning with urination
- back pain
- leg cramps or leg muscle pain
Order the MDASI-OC
- Purpose: To assess the severity of multiple symptoms related to ovarian cancer and the impact of these symptoms on daily functioning
- Population: Patients with symptoms caused by ovarian cancer and its treatment
- Assessment areas: Severity of multiple symptoms and the impact of symptoms on daily functioning during the last 24 hours
- Method: Self-report; paper-and-pencil form or tablet PC (self-administered or via interview), or telephone-based interactive voice response (IVR) system
- Time required: Five minutes
- Scoring: Please see the MDASI User's Guide
- Reliability: Cronbach alpha reliability ranges from 0.88 to 0.91
In response to the FDA's 2009 guidance for the pharmaceutical industry on the use of PRO measures in medical product development to support labeling claims, we have prepared a MDASI User's Guide to document the development and psychometric properties of the MDASI and its modules, including the MDASI-OC. The User Guide addresses the recommendations in the FDA guidance and establishes the MDASI's adequacy as a measure to support medical product claims.
Williams LA, Agarwal S, Bodurka DC, et al. Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. J Pain Symptom Manage 46(6): 837-845, 2013. PMCID: PMC3775907.
Sailors MH, Bodurka DC, Gning I, et al. Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol 130(2): 323-328, 2013. PMCID: PMC3713195.
Cleeland CS, Mendoza TR, Wang XS, et al. Assessing Symptom Distress in Cancer: The M. D. Anderson Symptom Inventory. Cancer 2000; 89:1634-1646.
Meyer LA, Nick AM, Shi Q, et al. Perioperative trajectory of patient reported symptoms: A pilot study in gynecologic oncology patients. Gynecol Oncol 136(3): 440-445, 3/2015.
Meyer LA, Shi Q, Iniesta MD, et al. Comparison of patient-reported symptom burden in patients with ovarian cancer undergoing primary vs. interval tumor-reductive surgery [abstract]. American Society of Clinical Oncology (ASCO) 53rd Annual Meeting, Chicago IL, Jun 2-6, 2017. J Clin Oncol 35(Suppl), 5/2017; Abstract #5557.
Meyer LA, Lasala J, Cain K, et al. Adoption of an enhanced recovery program leads to decreased patient reported opioid related adverse events [abstract]. International Society for Quality of Life Research (ISOQOL) 23rd Annual Conference, Copenhagen, Denmark, Oct 19-22, 2016. Qual Life Res 25(1 Supplement): 119, 10/2016; Abstract #2043.
Turner M, Monk B, Bodurka DC, et al. Patient-reported symptoms in ovarian cancer before and after disease progression in conjunction with bevacizumab maintenance therapy [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, Washington DC, May 21-25, 2016. Value Health 19(3): A158, 5/2016; Abstract #PCN138.
Meyer LA, Nick AN, Iniesta MD, et al Comparison of patient-reported symptom burden pre- and post-implementation of an enhanced recovery pathway for gynecologic surgery [abstract]. World Congress of Enhanced Recovery After Surgery and Perioperative Medicine, Washington DC, May 9-12, 2015. Can J Anesth 62(6): 683, 4/2015; Abstract #OR002.
Every MDASI Module Contains...
All 13 MDASI core symptoms
pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, difficulty remembering, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness/tingling
All 6 MDASI interference items
general activity, mood, work, relations with others, walking, enjoyment of life
Ovarian cancer has high rates of recurrence, making patient-reported symptoms important to capture potential treatment benefit and disease trajectory.
Michelle Turner, MS
ICON Clinical Research, USA